Stock Research for IMMY

IMMY

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

IMMY Stock Chart & Research Data

The IMMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IMMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


IMMY Due diligence Resources & Stock Charts

The IMMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IMMY Detailed Price Forecast - CNN Money CNN View IMMY Detailed Summary - Google Finance
Yahoo View IMMY Detailed Summary - Yahoo! Finance Zacks View IMMY Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View IMMY Trends & Analysis - Trade-Ideas Barrons View IMMY Major Holders - Barrons
NASDAQ View IMMY Call Transcripts - NASDAQ Seeking View IMMY Breaking News & Analysis - Seeking Alpha
Spotlight View IMMY Annual Report - CompanySpotlight.com OTC Report View IMMY OTC Short Report - OTCShortReport.com
TradeKing View IMMY Fundamentals - TradeKing Charts View IMMY SEC Filings - Bar Chart
WSJ View Historical Prices for IMMY - The WSJ Morningstar View Performance/Total Return for IMMY - Morningstar
MarketWatch View the Analyst Estimates for IMMY - MarketWatch CNBC View the Earnings History for IMMY - CNBC
StockMarketWatch View the IMMY Earnings - StockMarketWatch MacroAxis View IMMY Buy or Sell Recommendations - MacroAxis
Bullish View the IMMY Bullish Patterns - American Bulls Short Pains View IMMY Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View IMMY Stock Mentions - StockTwits PennyStocks View IMMY Stock Mentions - PennyStockTweets
Twitter View IMMY Stock Mentions - Twitter Invest Hub View IMMY Investment Forum News - Investor Hub
Yahoo View IMMY Stock Mentions - Yahoo! Message Board Seeking Alpha View IMMY Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for IMMY - SECform4.com Insider Cow View Insider Transactions for IMMY - Insider Cow
CNBC View IMMY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IMMY - OTC Markets
Yahoo View Insider Transactions for IMMY - Yahoo! Finance NASDAQ View Institutional Holdings for IMMY - NASDAQ


Stock Charts

FinViz View IMMY Stock Insight & Charts - FinViz.com StockCharts View IMMY Investment Charts - StockCharts.com
BarChart View IMMY Stock Overview & Charts - BarChart Trading View View IMMY User Generated Charts - Trading View




Latest Financial News for IMMY


Harrow Health Announces Fourth Quarter 2018 Financial Results
Posted on Tuesday March 12, 2019

SAN DIEGO, March 12, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the fourth quarter 2018. Fourth Quarter 2018 and Other Recent Notable Highlights:.


Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019
Posted on Monday March 04, 2019

Harrow Health, Inc. (HROW) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019 at The Ritz Carlton, Laguna Niguel in Dana Point, CA.  Mark L. Baum, the company’s Chief Executive Officer, and Andrew R. Boll, its Chief Financial Officer, will be hosting one-on-one meetings at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting. Harrow Health, Inc. (HROW) owns a portfolio of healthcare businesses, including the nation’s leading ophthalmology pharmaceutical compounding business, ImprimisRx.  The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, all companies founded as subsidiaries of Harrow Health.  The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley.  Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first.  For more information about Harrow Health, please visit the Investor Relations section of the corporate website by clicking here.


Harrow Health to Announce Fourth Quarter 2018 Financial Results on March 12, 2019
Posted on Thursday February 28, 2019

Harrow Health, Inc. (HROW) today announced it will release fourth quarter 2018 financial results after the close of trading on Tuesday, March 12, 2019.  The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30 p.m. Pacific Daylight Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (844) 369-8770 for domestic callers or (862) 298-0840 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Harrow Health website by clicking here.  A dial in replay of the call will be available until April 12, 2019.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 44882.  The webcast replay will be available until June 12, 2019.


Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations
Posted on Wednesday February 13, 2019

Melt Pharmaceuticals, Inc., a specialty pharmaceutical company recently deconsolidated from Harrow Health, Inc. (HROW), today announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations.  U.S. Patents 10,166,240 and 10,179,136 relate to methods of use, formulation compositions and methods to manufacture the same, which the company intends to commercialize through its MELT-100 program and other planned drug development initiatives.  Both new patents have expiration dates in 2036. Melt Pharmaceuticals, Inc., is a development stage specialty pharmaceutical company focused on the development and commercialization of patented non-opioid and non-intravenous (or non-IV) sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings.  Melt intends to seek regulatory approval through the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway for these proprietary technologies.  Melt’s core technology is a series of combination non-opioid sedation drug formulations that may replace or supplement current sedation modalities for more than 100 million medical procedures in the United States.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.